Description: Moderna (MRNA) closed the most recent trading day at $40.6, moving +2.52% from the previous trading session.

Description: We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of the top performers on Tuesday. Moderna rebounded by 17.02 percent on Tuesday to finish at $39.60 apiece as investors took heart from the preliminary results of its earnings performance in full-year 2025. At the […]

Description: The latest investor updates on stocks that are trending on Wednesday.

Description: More bank earnings and economic reports await going into Hump Day.

Description: Stocks fell Tuesday after the latest data from the Bureau of Labor Statistics showed inflation held steady in December as prices for goods and services rose 2.7%. JPMorgan Chase fell 4.2%. Earnings of $4.63 a share fell short of analysts’ calls for $4.85.

Description: The Dow and S&P 500 drop from record highs Tuesday, but Caterpillar was moving up toward a milestone.

Description: Market Domination Overtime Host Josh Lipton tracks several of the day's top trending stock tickers, including Adobe's stock (ADBE) downgrade to Market Perform from Oppenheimer analysts, Moderna (MRNA) providing an upbeat update to its guidance, and the team out of BNP Paribas downgrades both of its ratings on FedEx (FDX) and United Parcel Service (UPS). To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: Major US equity indexes closed lower Tuesday as investors weighed bank earnings and December inflati

Description: A Relative Strength Rating upgrade for Moderna shows improving technical performance. Will it continue?

Description: Moderna stock, depressed for so long, is breaking out—and the gains could keep coming. Moderna rounded out a bottom in 2025, and the stock is now putting its foot on the accelerator in 2026. Wit the stock trading at a trecent $38.50 on Tuesday, a longer term double bottom with handle looks to be forming.

Description: Capital One and American Express stocks decline after President Donald Trump calls for a cap of 10% on credit-card interest rates.

Description: Health care stocks were mixed late Monday afternoon, with the NYSE Health Care Index up 0.1% and the

Description: Moderna offered investors a glimpse at its upcoming earnings report as it pre-announced revenue above the midpoint of its prior guidance range. Presenting at the annual J.P. Morgan Healthcare Conference on Monday, Moderna said it expects 2025 revenue of roughly $1.9 billion, $100 million above the midpoint of the range communicated on the company’s third-quarter earnings call. The company still expects revenue growth of up to 10% in 2026, and reiterated that it expects non-adjusted operating expenses to decline to $4.9 billion from a range of $5 billion to $5.2 billion in 2025.

Description: Moderna (MRNA) said Monday that it expects its 2025 revenue to come in close to the top end of its g

Description: Commonwealth Fusion Systems (CFS), the largest and leading private fusion company, today announced that Stephane Bancel, the Chief Executive Officer of Moderna Inc. who led that company's successful development, production, scaling, and global adoption of the COVID-19 vaccine, has joined as an Independent Member of the Board of Directors.

Description: Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call Improves 2025 expected GAAP operating expenses by $200 million since 3Q25 Earnings Call Increases 2025 projected year-end ...

Description: In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, supported by positive Phase 3 data showing relative vaccine efficacy of about 27% and a favorable safety profile. This move marks a key test of Moderna’s effort to extend its mRNA platform beyond COVID-19, potentially broadening its respiratory vaccine portfolio and reducing reliance on a single product...

Description: In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day.

Description: Wall Street closed sharply higher on Tuesday, led by materials, healthcare and chip stocks.

Description: Pre-Market Stock Futures: The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit another record high, closing over $49,000 for the first time at $49,484, up a solid 1.04%. The S&P 500 also posted a record high, closing at 6,947, up 0.66%. The ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonald’s, Moderna, and More

Description: (Updates with BioNTech response in the sixth paragraph.) Bayer's Monsanto unit filed patent infri

Description: Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Description: Bayer's Monsanto unit filed patent infringement lawsuits Tuesday against COVID-19 vaccine makers Pfi

Description: Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.

Description: Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational ...

Description: The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Description: Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 months, even as its one year return remains negative. See our latest analysis for Moderna. That recent 11% 1 month share price return looks more like early momentum than a full turnaround, especially when set against Moderna’s 1 year total shareholder return of negative 26.8% and deeply negative multi year performance. If Moderna’s move has you rethinking healthcare...

Description: In the closing of the recent trading day, Moderna (MRNA) stood at $30.41, denoting a -2.38% move from the preceding trading day.

Description: This stock is a great choice for cautious and aggressive investors.

Description: Nvidia is rising after reaching an agreement with AI start-up Groq, while Lam Research stock is on track for a record high.

Description: Moderna stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 67 to 73. See if Moderna stock can continue to rebound and clear that threshold. Moderna stock tried to breakout of a cup-shaped base on Dec. 22, but has pulled back slightly.

Description: It’s been a “low volatility holiday season,” according to Citigroup strategists, but don’t expect it to stay that way heading into 2026. The S&P 500 is down 0.1%, while the Dow Jones Industrial Average is down 0.2%, and the Nasdaq Composite is little changed. The CBOE Volatility Index, or VIX, is still trading below 14, though it has ticked up a touch today.

Description: The day after Christmas is supposed to be one of the better days of the year. It’s not looking like that right now. After trading higher to start the day, the S&P 500 has dipped 0.04%, while the Dow Jones Industrial Average and Nasdaq Composite have slipped 0.

Description: The main US stock measures were trending lower in Wednesday's premarket activity as investors prepar

Description: The latest trading day saw Moderna (MRNA) settling at $32.29, representing a -7.48% change from its previous close.

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.8% in the afternoon session after the stock's positive momentum continued as the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would invest up to $54.3 million to support a pivotal Phase 3 clinical trial for the company's investigational mRNA-based pandemic influenza vaccine candidate, mRNA-1018.

Description: Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.

Description: Your decision on whether to invest now depends to some extent on your investment strategy.

Description: Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 bird flu vaccine candidate, mRNA-1018. See our latest analysis for Moderna. The CEPI funding has helped extend a short burst of momentum, with Moderna’s 1 month share price return of 23.22 percent contrasting sharply with a 1 year total shareholder return of negative 20.46 percent. This suggests sentiment is improving, but the longer term recovery story is still being...

Description: We came across a bullish thesis on Moderna, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc.’s share was trading at $29.92 as of December 15th. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. MRNA’s strategy from 2025–2030 emphasizes capital efficiency […]

Description: With federal funding cut, Moderna finds new backers for its pandemic play--just as mRNA faces a critical test

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a late-stage trial for its experimental bird flu vaccine.

Description: The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government funding.

Description: Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza ...

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.

Description: CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT. A live webcast of the presentation ...

Description: CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.

Description: The European Medicines Agency’s Committee for Medicinal Products for Human Use previously issued a positive opinion recommending marketing authorization of Moderna’s new COVID-19 vaccine, mNEXSPIKE (mRNA-1283), for individuals aged 12 and older, following Phase 3 data showing higher relative efficacy versus Spikevax. This potential EU approval would broaden Moderna’s respiratory vaccine lineup and regional footprint, partly counterbalancing pressure from weakening COVID-19 vaccine...

Description: The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.

Description: Barron’s capitalized on the trends with Alibaba Group Holding Alphabet and ASML Holding as well as other winners, including Citigroup and Uber Technologies in our top 10 picks for 2025. Rounding out the list is pharmaceutical turnaround candidate Bristol Myers Squibb which yields almost 5%.

Description: mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the European Union, subject to authorization by the ...

Description: Roblox downgraded, Lululemon upgraded: Wall Street's top analyst calls

Description: Barron’s capitalized on the trends with Alibaba Group Holding Alphabet and ASML Holding as well as other winners, including Citigroup and Uber Technologies in our top 10 picks for 2025. Rounding out the list is pharmaceutical turnaround candidate Bristol Myers Squibb which yields almost 5%.

Description: Noubar Afeyan says American hesitation is creating a strategic opening China is moving fast to exploit.

Description: Stéphane Bancel: Thank you, Lavina. In the third quarter of 2024 compared to the first quarter of 2023, we reduced operating expenses by $500 million across cost of sales, RD and SG&A. This figure excludes $1.4 billion of resizing charge in the first quarter of 2023. Stéphane Bancel: This year, the COVID market benefited from U.S. regulatory approval that was 19 days earlier than in 2023.

Description: Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent dosing.

Description: Stéphane Bancel: In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, mRESVIA. Stéphane Bancel: During the quarter, we made good progress across our 3 strategic priorities. For Spikevax, our original COVID vaccine, we received approval in 40 countries for the seasonal 2025-2026 strain update.

Description: Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that it had secured a five-year loan of $1.5 billion from Ares Management Corp (NYSE:ARES). The company made this announcement as it prepared to unveil strategy updates to analysts later that day. Moderna plans to […]

Description: Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Description: Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

Description: Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the discount rate from 7.13% to 7.13%, reflecting a slightly higher required return amid ongoing debates around execution risk and cash sustainability. Long term revenue growth expectations have also eased from 10.31% to 10.22%, as models balance stronger liquidity and oncology optionality against litigation and pipeline uncertainties. Stay tuned to see how you can track these...

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.

Description: Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Description: VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.

Description: Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied to a review of reported child fatalities following COVID 19 vaccinations. See our latest analysis for Moderna. That 6% drop sits on top of a steep year to date share price return of around negative 43%, and with one year total shareholder return also down sharply, it suggests sentiment is still fragile and recent momentum is fading despite episodic regulatory and...

Description: Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.

Description: Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.

Description: MILLBRAE, Calif., December 02, 2025--Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with cutting-edge research to accelerate drug discovery, today announced the election of David W. Meline as an independent director effective November 23, 2025. Mr. Meline is the former Chief Financial Officer at Moderna Inc.

Description: Companies In The Article Are: SNPS,DIS,CPNG,MRNA

Description: December S&P 500 E-Mini futures (ESZ25) are up +0.27%, and December Nasdaq 100 E-Mini futures (NQZ25) are up +0.39% this morning, signaling a rebound from yesterday’s sell-off on Wall Street as investor risk appetite gradually returns at the start of December, a period that has historically been strong for markets.

Description: Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s prospects.

Description: Moderna recently faced pressure after the U.S. Food and Drug Administration announced plans to require more rigorous safety and efficacy evidence for vaccine approvals, following reports of child fatalities linked to COVID-19 vaccinations. This regulatory overhaul is expected to increase development hurdles for vaccine makers, posing significant new challenges for Moderna’s ongoing innovation and pipeline expansion. We’ll explore how heightened regulatory scrutiny could shape Moderna’s...

Description: December did not start well for the market, with all the major indices in the red. Will the theories urging caution against expecting a Santa Claus rally hold? Well, this is just Day 1, and for some, the Christmas tree decorations are still pending. So let us not entirely give up on the holiday ...

Description: Worries about regulatory headwinds weighed on vaccine producers on Monday, Dec. 1, 2025, while a chip design software maker got a boost from a partnership with an AI darling.

Description: Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.

Description: The Dow fell on the stock market today. Moderna skidded after an FDA memo linked Covid vaccines to deaths. A gold stock cleared an entry.

Description: Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become stricter.

Description: Moderna falls after the Food and Drug Administration said in a memo last week it would place new restrictions on which vaccines hit the market. Bloomberg News reporter Gerry Smith discussed the story on "Bloomberg Markets" with Katie Greifeld.

Description: Yahoo Finance host Julie Hyman kicks off Yahoo Finance's Market Minute with some of the top stories of Monday's trading session, including Nvidia's (NVDA) investment in Synopsys (SNPS), Disney's (DIS) "Zootopia 2," and vaccine stock moves. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back.

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the stock hit vaccine makers Moderna (MRNA), BioNTech (BNTX), and Novavax (NVAX) are taking on following a memo from the US Food and Drug Administration (FDA); casino operator Bally's (BALY) has won approval to run casinos in New York City; and Somnigroup International's (SGI) $1.6 billion offer to acquire Leggett & Platt (LEG). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Description: Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official claimed the shots led to 10 children’s deaths and said the agency would tighten vaccine-approval standards. Shares of Moderna and Novavax, which depend heavily on Covid-19 vaccine sales for revenue, fell about 6% and 3.5%, respectively. Stock in Pfizer, whose Covid-19 vaccine sales are a smaller percentage of total company revenue, ticked higher.

Description: Vinay Prasad, a top FDA official, blamed Covid shots for playing a role in the deaths of 10 children in the memo he sent to agency staff on Friday, which was seen by Bloomberg. Moderna, which produces Covid shots, fell 4.1% at the start of regular trading in New York on Monday.

Description: Investing.com -- Shares in major COVID-19 vaccine makers fell on Monday after an internal U.S. Food and Drug Administration (FDA) memo reportedly suggested that vaccinations may have contributed to several child deaths linked to heart inflammation.

Description: Emerging market opportunities include advanced therapies for RSV, COVID-19, UTIs, HIV, and fungal infections, with promising candidates such as Moderna's mRNA assets, GSK's TBP-PI-HBr, and Armata's AP-SA02. Focus on innovative strategies in viral, bacterial, and fungal infection management.Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "IDWeek: Annual Meeting 2025 Highlights" report has been added to ResearchAndMarkets.com's offering.IDWeek is the joint annual meeting of the Infectious Diseases S

Description: President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.

Description: Vaccine-maker Moderna has become the most shorted company in the S&P 500, with its share price slumping to its lowest level since before the...

Description: Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This change reflects revised expectations for the company's long-term potential. The adjustment comes as revenue growth projections have been reduced from 18.75% to 10.31%, with analysts weighing bullish signals against lingering macro and operational challenges. Stay tuned to discover how investors can stay ahead of these evolving perspectives on Moderna's future...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C

Description: The initiative forms part of Moderna’s continued investment in US-based infrastructure.

Description: Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.

Description: Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase ...

Description: Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028 CAMBRIDGE, MA / ACCESS Newswire ...

Description: At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth in 2027 and 2028.”

Description: Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the

Description: Health care stocks traded mixed Wednesday afternoon, with the NYSE Health Care Index up 0.1% and the

Description: Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, investors are shifting focus to its cancer pipeline.

Description: For the first time, security, IT and IAM teams can manage AI agent identities from discovery to deprovisioning to eliminate blind spots, enforce least privilege, and secure the next evolution of identity and access management NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Token Security, the leader in Agentic Identity security, today announced new AI Agent Identity Lifecycle Management capabilities which empower enterprises to discover, govern, manage, and secure the rapidly growing population of A

Description: New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November ...

Description: A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.

Description: CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annual Healthcare Conference, on Tuesday, December ...

Description: Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major market.

Description: Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above Wall Street expectations for both revenue and earnings. Management attributed the outperformance to rigorous cost discipline, with CEO Stéphane Bancel noting a 34% reduction in combined cost of sales, R&D, and SG&A compared to last year. The company also cited strong market uptake of its new COVID vaccine, mNEXSPIKE, and the impact of ongoing productivity initiatives. CFO Jam

Description: The main US stock measures were pointing higher in Wednesday's premarket activity as traders await a

Description: OXFORD, United Kingdom, November 10, 2025--A major new regional partnership, Equinox (Equitable Innovation Oxford) has officially launched to establish Oxford as a global centre for innovation and entrepreneurship.

Description: Are Wall Street analysts favoring Moderna’s stock?

Description: In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the previous year, alongside a net loss of US$200 million and lowered full-year revenue guidance to US$1.6–2 billion. An interesting detail is that, while COVID vaccine demand softened and Moderna discontinued its CMV vaccine development, the company maintained cost reductions and advanced key regulatory filings and product launches. To assess how these developments impact...

Description: As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest quarterly results with some very strong...

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1%

Description: Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se

Description: Moderna (MRNA) continues to target cash breakeven in 2028, banking on its ongoing cost reductions an

Description: Moderna’s stock narrative has experienced a notable shift following recent analyst updates. The consensus fair value is holding steady at $40.30, and revenue growth projections have moved sharply higher. Analysts point to evolving developments in Moderna’s clinical pipeline and a slightly increased discount rate as key drivers of the changed outlook. However, views remain mixed on the company’s near-term prospects. Stay tuned to discover how investors can monitor emerging trends that could...

Description: India's Coronavirus Vaccine Market offers growth through government-led initiatives, robust manufacturing, and R&D in vaccine types. Opportunities arise from vaccine diplomacy, expanding healthcare in Tier 2 and 3 cities, and innovations like mRNA technology. Challenges include vaccine hesitancy and misinformation. Indian Coronavirus Vaccine Market Indian Coronavirus Vaccine Market Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The "India Coronavirus Vaccine Market, By Region, By Competition, Opportu

Description: Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $1.8 billion at the midpoint came in 4.4% below analysts’ estimates. Its GAAP loss of $0.51 per share was 78.6% above analysts’ consensus estimates.

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to easily beat sales expectations.

Description: The major gauges have reached a holding pattern in a volatile week with investors seeking firm news on tariffs, earnings and Tesla.

Description: Yahoo Finance anchor Josh Lipton recaps three of the top stories investors are watching as part of Yahoo Finance's Market Minute, including Vistra's (VST) revenue miss, Moderna's (MRNA) narrower-than-expected loss, and Tapestry's (TPR) weak outlook. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: Moderna Inc (MRNA) navigates a challenging quarter with significant cost reductions and strategic partnerships, despite a decline in COVID vaccine demand.

Description: MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

Description: Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on Thursday. Sales of Moderna’s respiratory syncytial virus, or RSV, vaccine remain negligible, and the company had a net loss of $200 million for the quarter. The quarter’s revenue of $1 billion beat the FactSet consensus estimate of $900 million.

Description: Moderna (MRNA) narrowed its full-year revenue outlook on Thursday as the drugmaker's third-quarter t

Description: Moderna shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its cost-cutting measures are helping offset the decline of its Covid business. Gerry Smith reports on "Bloomberg Open Interest."

Description: The company posted a net loss of 51 cents a share, against Wall Street’s expectation for a loss of $2.21. Moderna has aggressively reduced costs through measures including staff cuts and lower spending on research and manufacturing to offset slowing vaccine sales. The company still has a goal of breaking even by 2028, Moderna Chief Financial Officer Jamey Mock said in an interview.

Description: The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad

Description: Moderna (MRNA) delivered earnings and revenue surprises of +76.28% and +18.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $1.8 billion at the midpoint came in 4.4% below analysts’ estimates. Its GAAP loss of $0.51 per share was 78.6% above analysts’ consensus estimates.

Description: Investing.com - Moderna has reported a sharp drop in third-quarter revenue, but still topped Bloomberg consensus estimates, while the drugmaker also trimmed its full-year sales forecast.

Description: MRNA) on Thursday reported a loss of $200 million in its third quarter. On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 51 cents. The results exceeded Wall Street expectations.

Description: Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to break even financially in 2028 with the help of more disciplined spending.

Description: Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.

Description: Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - ...

Description: The major gauges have reached a holding pattern in a volatile week with investors seeking firm news on tariffs, earnings and Tesla.

Description: Moderna reports earnings early Thursday as investors wonder whether the biotech will run through its pandemic-era windfall before it stops losing money. The vaccine company had accumulated nearly $20 billion in cash by early 2022, thanks to the record-smashing sales of its Covid-19 shot, but has been losing billions of dollars a year since 2023. Management has said Moderna will have $6 billion left at the end of this year, will stop losing money in 2028, and won’t need to raise any new cash to bridge the gap.

Description: The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics Market Report 2025" has been added to ResearchAndMark

Description: Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Thursday before the bell. Here’s what investors should know.

Description: Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer research as it moves beyond COVID-19 vaccines. See our latest analysis for Moderna. Despite excitement over cancer-vaccine partnerships and high-profile buyout speculation, Moderna’s share price return is down 40.7% year-to-date. This reflects a tough run as investors reassess risk after mixed...

Description: MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its financial performance and a recent clinical setback overshadowed an announcement about a new, early-stage study.

Description: CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants ...

Description: George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.5% in the afternoon session after the stock retreated, giving back some of the strong gains from the previous session that were fueled by reports of potential buyout or partnership discussions.

Description: Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Description: Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Description: A social media giant faltered on Thursday, Oct. 30, 2025, as a tax event weighed on its results, while a biotech name benefitted from reports of talks with a major pharma player.

Description: Investing.com -- Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a deal of significant scope," which could include a potential acquisition.

Description: Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Description: When the S&P 500 is rallying to all-time highs, you have to wonder about the stocks getting left out. Turns out analysts see great promise.

Description: BOSTON, October 27, 2025--Harvard Business Review announces final lineup for Future of Business 2025, its Nov. 3 virtual conference featuring top global leaders and thinkers.

Description: Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

Description: Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, mRNA-1647, following disappointing results from a Phase 3 clinical trial that did not meet its primary efficacy endpoint in seronegative women of childbearing age. This decision marks a setback for one of Moderna’s most advanced late-stage programs, highlighting the ongoing risks and volatility inherent in late-stage vaccine development. We’ll assess how discontinuing...

Description: Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

Description: Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index shedding 0.1%

Description: CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive ...

Description: Health care stocks edged lower Thursday afternoon, with the NYSE Health Care Index easing 0.1% and t

Description: Yahoo Finance senior reporter Allie Canal keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Tesla (TSLA), Zions Bancorporation (ZION), and Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The event will include presentations from management ...

Description: Moderna is expected to announce its third-quarter results next month, and analysts expect a significant loss per share.

Description: Moderna (MRNA) closed at $26.85 in the latest trading session, marking a -2.33% move from the prior day.

Description: A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, heightening pressure on Moderna’s flagging respiratory vaccine business.

Description: Moderna is stopping development of a vaccine designed to prevent birth defects caused by cytomegalovirus, or CMV, once among its most-watched experimental programs. CMV infections generally don’t cause symptoms in adults, but babies who contract the virus during pregnancy can suffer long-term health effects. The Moderna jab would have needed to fully prevent infections in pregnant mothers, not just tamp down symptoms, to protect infants from birth defects.

Description: Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate any impact to its 2025 financial guidance or its ...

Description: The biotech's innovative qualities will come in handy.

Description: This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Wednesday. This is TheStreet’s Stock Market Today for Oct. 22, 2025. You can follow the latest updates on the ...

Description: Shares could keep sliding, as Moderna's post-COVID pipeline has yet to reach a breakthrough.

Description: Moderna’s story is far from over, but it needs patience and successful execution.

Description: Don't try to catch a falling surgical knife.

Description: The 221-acre site sits next to the Harwell Science and Innovation Campus in Oxfordshire.

Description: Moderna (MRNA) shares have been volatile lately, drawing fresh attention as investors weigh the company’s prospects beyond COVID-19 vaccines. With its next earnings report approaching, the market is watching for signs of future growth. See our latest analysis for Moderna. After a tough stretch for Moderna, the share price has slid 38% year to date, and the total shareholder return over the past year is even deeper in the red at -52%. Some short-lived rallies have popped up, but recent price...

Description: Super Micro Computer stock was on pace to end Monday’s session as the top performer in the index, as bullish attitudes on Wall Street lifted shares higher. The stock snapped a two-day losing streak and rose 6.3% to $55.65, hovering below its 52-week high of $66.44. Super Micro, which makes servers and storage products for data centers, falls into the broader category of artificial intelligence-linked names that have seen explosive gains lately.

Description: The Dow Jones index was up Monday but lagged the Nasdaq. Cleveland-Cliffs soared on the stock market today. Amazon rose amid an AWS outage.

Description: Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Description: CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the ...

Description: Moderna (MRNA) shares were down almost 5% in recent trading on Friday after management provided an u

Description: Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, Moderna announced that promising clinical, safety, and translational data from its Phase 1/2 study evaluating the investigational immune-evasion targeted cancer antigen therapy/CAT mRNA-4359 would be presented at the 2025 European Society for Medical Oncology/ESMO […]